The role of nocebo effects in identifying patients at risk for pain progression in fibromyalgia

eiden University0 个研究点目标入组 137 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

•Participants must meet all of the following criteria:
•Fluent in Dutch language (written and spoken)
•Able to give informed consent
•Additionally, for patients:
•Fibromyalgia diagnosis by a rheumatologist, as reported by the patient and as verified by provision of the date, location, and provider of the diagnosis.

•Participants will be excluded for the following criteria:
•Pregnancy or breastfeeding
•Color blindness
•Injuries/open wounds on the non-dominant hand or arm on the day of laboratory session
•Carrying a pacemaker/implanted pumps
•Having implanted metals on the non-dominant hand or arm
•Refusal/inability to remove possible artificial nails or nail polish covering the thumbnail
•Specific for patients, additionally:
•A medical diagnosis other than fibromyalgia explaining the chronic pain symptoms
•Severe physical or mental co-morbidities that are not related to fibromyalgia symptoms (e.g., DSM-V diagnosis of psychosis, suicidal ideation, addiction)
•Use of painkillers different than usual dose of treatment on the day of experimentation
•Specific for healthy controls, additionally:
•Chronic pain complaints =3 months in the past or present or a diagnosis of fibromyalgia
•Current pain
•Severe physical or psychiatric co-morbidities that may interfere with the study protocol (e.g., DSM-V diagnosis)
•Use of painkillers within 24 hours before the day of experimentation

发起方

eiden University